求助6篇Springer数据库文献

w2503

1. Clinical Applications of Activated Immune Cells' m: t& C" ]) A' ?/ S% f% a. P
http://www.springerlink.com/content/p77j27781g92vm53/* p: @) l0 x4 y; y
, D9 u8 P( h$ l" n0 z$ f. U
2. Increased effector–target cell conjugate formation due to HLA restricted specific antigen recognition
- N5 `9 c# X/ ihttp://www.springerlink.com/content/l667677h47l82363/
8 }; `' T/ H& j- _6 l* U7 Z6 Z! ~/ `5 m0 o
3. Selective Immortalization of Tumor-Specific T Cells to Establish Long-Term T-Cell Lines Maintaining Primary Cell Characteristics   r* Q: w1 i: s$ k3 i. }
http://www.springerlink.com/content/lg3m7811288qg086/#section=54582&page=1* E4 |- a' S8 b" P

- y8 U! n3 N( i4 [: U4 k4. Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancer) u7 V, A/ w( _
http://www.springerlink.com/content/u67186375261m831/4 v& i, q. i# E8 P7 t+ z
4 ~* Y- \$ Y% V. |. X
5. Gene Immunotherapy for Non-Small Cell Lung Cancer & d6 c" _- A; C' G
http://www.springerlink.com/content/w2j70l9rx1857154/#section=671351&page=1
0 W1 J- t$ L/ F, D; o# n8 y2 m+ b) Y/ Q. z6 h( a# Y
6. Designing TCR for Cancer Immunotherapy! `/ z9 _' g3 X( [& K! z
http://www.springerlink.com/content/v7607l2v0243k7m7/#section=83660&page=1, t5 o3 I) B" n) i. B  t
* J( f: N* ^' p- ]  s$ `
谢谢% z  d$ F1 z5 w6 }% {8 f0 }
  ?( a1 |7 c) H* B
' V& Z4 k* o0 ]9 ]. m9 O
& h/ _- X( j5 Q$ G) Q+ \9 P  I9 ^
/ A+ D+ k" S% C, L6 M7 `5 v. E

sunlu36

1 ok

sunlu36

3 ok+ ^& B0 u! l& V

sunlu36

4   

sunlu36

5     

sunlu36

6     

w2503

回复 sunlu36 的帖子- m. N2 Y1 t, s. A7 M0 m7 E
! o  Y$ z, A9 q7 `: |. l
谢谢

w2503

2 W" z# W+ ]/ V) T
( Q, I) |% ]  v+ G: `* \还差第2篇1 z3 E/ v) A) T1 l( z. z4 b- U; @( L
2. Increased effector–target cell conjugate formation due to HLA restricted specific antigen recognition / W" F+ m! C( M' Y
http://www.springerlink.com/content/l667677h47l82363/

ceming

2 check the attached file

w2503

回复 ceming 的帖子
" ^$ h  z5 w( ^3 c! Q/ \& ^
' @) N+ S0 X& h谢谢